Jie Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jie Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Chao Chen
Department of Critical Care Medicine Henan Provincial People's Hospital, Zhengzhou University People's Hospital Zhengzhou Henan China
1 shared publication- Jiajia Han
Department of Infectious Diseases Henan Provincial People's Hospital, Zhengzhou University People's Hospital Zhengzhou Henan China
1 shared publication - Liping Du
Department of Ophthalmology Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Henan Province Eye Hospital, The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China
1 shared publication Liyun Zheng
Henan Institute of Medical and Pharmaceutical Sciences Zhengzhou University Zhengzhou Henan China
1 shared publication- Yalong Dang
Department of Ophthalmology, Sanmenxia Eye Hospital/Sanmenxia Central Hospital Affiliated to Henan University of Science and Technology, Sanmenxia, China
1 shared publication Ying Peng
Henan Institute of Medical and Pharmaceutical Sciences Zhengzhou University Zhengzhou Henan China
1 shared publication
Latest Publications
- Open Access
- 6 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9) , e70694
Twisting the End Game: How Telomere Chromatin Modifications Shape Telomere Maintenance
Cell division inevitably shortens telomeric DNA owing to the end‐replication problem. Eukaryotic chromosomes possess specialized telomere structures to maintain genomic stability. In most proliferative cells, telomerase adds telomeric repeats during S‐phase. In differentiated cells where telomerase is silenced, telomeres shorten progressively, thereby compromising genomic integrity. Consequently, cancer cells universally activate alternative telomere maintenance mechanisms during malignant transformation: ~80% reactivate telomerase, while a portion of the rest rely on BIR (break‐induced replication)–mediated homologous recombination‐based ALT (alternative lengthening of telomeres). Although these mechanisms are stable once established, the initial determinants influencing a cancer cell's choice remain poorly understood. This review discusses recent molecular insights into how telomeric chromatin properties profoundly impact this choice. After briefly introducing telomere chromatin characteristics and key players in its maintenance and dynamics, we discuss the mechanisms by which cancer cells acquire distinct telomere replication capabilities. In particular, we present an in‐depth analysis linking telomere heterochromatin status to ALT. Furthermore, based on recent advances, we propose a coupled feedforward loop model explaining how the ALT state becomes “locked in” once initiated. Finally, we offer novel perspectives on rational, telomere‐centric therapeutic interventions for ALT‐positive cancers, focusing on strategies designed to disrupt such feedforward loops by manipulating telomeric chromatin structure.
- 6 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9) , e70694
Open AccessTwisting the End Game: How Telomere Chromatin Modifications Shape Telomere Maintenance
Cell division inevitably shortens telomeric DNA owing to the end‐replication problem. Eukaryotic chromosomes possess specialized telomere structures to maintain genomic stability. In most proliferative cells, telomerase adds telomeric repeats during S‐phase. In differentiated cells where telomerase is silenced, telomeres shorten progressively, thereby compromising genomic integrity. Consequently, cancer cells universally activate alternative telomere maintenance mechanisms during malignant transformation: ~80% reactivate telomerase, while a portion of the rest rely on BIR (break‐induced replication)–mediated homologous recombination‐based ALT (alternative lengthening of telomeres). Although these mechanisms are stable once established, the initial determinants influencing a cancer cell's choice remain poorly understood. This review discusses recent molecular insights into how telomeric chromatin properties profoundly impact this choice. After briefly introducing telomere chromatin characteristics and key players in its maintenance and dynamics, we discuss the mechanisms by which cancer cells acquire distinct telomere replication capabilities. In particular, we present an in‐depth analysis linking telomere heterochromatin status to ALT. Furthermore, based on recent advances, we propose a coupled feedforward loop model explaining how the ALT state becomes “locked in” once initiated. Finally, we offer novel perspectives on rational, telomere‐centric therapeutic interventions for ALT‐positive cancers, focusing on strategies designed to disrupt such feedforward loops by manipulating telomeric chromatin structure.